In this analysis of pooled phase 3 studies in psoriatic arthritis, secukinumab improved disease burden as measured by the GRAPPA-OMERACT domains, regardless of previous tumor necrosis factor inhibitor (TNFi) exposure

Higher responses in the TNFi-naive vs TNFi-inadequate responder/intolerant (TNF-IR) cohorts, especially in musculoskeletal manifestations and patient-reported outcomes, suggest value of secukinumab as a first-line biologic therapy for the treatment of psoriatic arthritis

Significant improvements in psoriasis and psoriasis-related patient-reported outcomes in both TNFi-naive and TNFi-IR patients receiving secukinumab 300 mg vs placebo suggest that secukinumab is an effective treatment option throughout the course of psoriatic disease